Targeting tau starts to show results in Alzheimer's
This article was originally published in Scrip
Executive Summary
Two compounds designed to tackle the tau pathology of Alzheimer's disease, TauRx Therapeutics' Rember and Allon Therapeutics' AL-108, have shown encouraging results in Phase II data presented at the International Conference on Alzheimer's Disease in Chicago.